Breakthrough Therapy Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Breakthrough Therapy stocks.

Recent Signals

Date Stock Signal Type
2021-05-14 ACHL Lower Bollinger Band Walk Weakness
2021-05-14 ACHL NR7 Range Contraction
2021-05-14 ASND Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-05-14 CMPS NR7 Range Contraction
2021-05-14 CMPS Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-05-14 GLTO New 52 Week Low Weakness
2021-05-14 GLTO Lower Bollinger Band Walk Weakness
2021-05-14 GLTO New 52 Week Closing Low Bearish
2021-05-14 GMAB Bollinger Band Squeeze Range Contraction
2021-05-14 GMAB Crossed Above 200 DMA Bullish
2021-05-14 REGN NR7 Range Contraction
2021-05-14 REGN Upper Bollinger Band Walk Strength
2021-05-14 VRTX Bollinger Band Squeeze Range Contraction
2021-05-14 VRTX Crossed Above 50 DMA Bullish
2021-05-14 VRTX Crossed Above 20 DMA Bullish

Recent News for Breakthrough Therapy Stocks

Date Stock Title
May 16 REGN Covid-19 Drugmakers Take On Your Favorite TV Shows to Tackle Vaccine Hesitancy
May 16 VRTX 4 Surefire Value Stocks to Buy for a Biden Bull Market
May 14 CMPS Compass Releases Q1 Earnings: Strong Cash Position For Psilocybin R&D Efforts
May 14 GLTO Galecto (GLTO) Investor Presentation - Slideshow
May 14 REGN COVID-19 vaccinations and mitigation turned the corner on school reopening: AFT President
May 14 REGN People choosing to ditch their masks will be a ‘gradual process’: Doctor
May 14 REGN Polen Focus Growth Fund Disposed its Regeneron Pharmaceuticals (REGN) Position, Here’s Why
May 14 VRTX Dogecoin's Biggest Weakness Is the Greatest Strength for These 2 Stocks
May 14 ASND We're Not Very Worried About Ascendis Pharma's (NASDAQ:ASND) Cash Burn Rate
May 14 VRTX Cathie Wood Sheds $33.6M Alibaba Shares On Earnings Day
May 14 REGN Cathie Wood Sheds $33.6M Alibaba Shares On Earnings Day
May 14 CMPS COMPASS Pathways plc (CMPS) Q1 2021 Earnings Call Transcript
May 13 REGN CDC approves those fully vaccinated to largely ditch masks indoors
May 13 REGN The Zacks Analyst Blog Highlights: Regeneron, Moderna, Minerva Neurosciences, Amgen and Biogen
May 13 CMPS COMPASS Pathways ADS reports Q1 results
May 13 CMPS COMPASS Pathways plc announces financial results and business highlights for the first quarter 2021
May 13 VRTX Forget Dogecoin: These Unstoppable Stocks Are Much Smarter Buys
May 13 VRTX 3 Mistakes to Avoid When Investing in Biotech Stocks
May 13 REGN Cathie Wood Piles Up Palantir For Third Day In A Row, Adding $39M Worth Of Shares
May 13 VRTX Vertex: While The Market Remains Indifferent, Now Is The Time To Commit

Breakthrough therapy is a United States Food and Drug Administration designation that expedites drug development that was created by Congress under Section 902 of the 9 July 2012 Food and Drug Administration Safety and Innovation Act. The FDA's "breakthrough therapy" designation is not intended to imply that a drug is actually a "breakthrough" or that there is high-quality evidence of treatment efficacy for a particular condition; rather, it allows the FDA to grant priority review to drug candidates if preliminary clinical trials indicate that the therapy may offer substantial treatment advantages over existing options for patients with serious or life-threatening diseases. The FDA has other mechanisms for expediting the review and approval process for promising drugs, including fast track designation, accelerated approval, and priority review.

More about Breakthrough Therapy
Browse All Tags